Oric Pharmaceuticals (ORIC) Non-Current Assets (2019 - 2026)
Oric Pharmaceuticals' (ORIC) quarterly Non-Current Assets came in at $146.5 million in Q1 2026, up 366.28% YoY from $31.4 million in Q1 2025, and up 21.68% on a QoQ basis from $120.4 million in Q4 2025.
Oric Pharmaceuticals (ORIC) Non-Current Assets (2019 - 2026) Analysis & Trends
Oric Pharmaceuticals (ORIC) has 8 years of Non-Current Assets data on file, last reported at $146.5 million in Q1 2026.
- Quarterly Non-Current Assets rose 366.28% year-over-year to $146.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $458.3 million (up 357.07% YoY) and the FY2025 annual result came in at $120.4 million, up 912.65% from the prior year.
- Non-Current Assets grew to $146.5 million in Q1 2026, from $120.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $146.5 million in Q1 2026 to a low of $11.9 million in Q4 2024.
- A 5-year average of $50.7 million and a median of $36.0 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets plunged 69.82% — and 2025, when it soared 912.65%.
- Tracing ORIC's Non-Current Assets over 5 years: stood at $36.7 million in 2022, then gained by 7.32% to $39.4 million in 2023, then sank by 69.82% to $11.9 million in 2024, then soared by 912.65% to $120.4 million in 2025, then climbed by 21.68% to $146.5 million in 2026.
- The last three Non-Current Assets figures came in at $146.5 million (Q1 2026), $120.4 million (Q4 2025), and $135.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Oric Pharmaceuticals | 1.44 Bn | 1.44 Bn | - | 130.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 130.99 Mn |
| Mar 31, 2026 | 146.53 Mn |
| Dec 31, 2025 | 120.42 Mn |
| Sep 30, 2025 | 135.60 Mn |
| Jun 30, 2025 | 55.73 Mn |
| Mar 31, 2025 | 31.43 Mn |
| Dec 31, 2024 | 11.89 Mn |
| Sep 30, 2024 | 22.64 Mn |
| Jun 30, 2024 | 34.31 Mn |
| Mar 31, 2024 | 26.70 Mn |
| Dec 31, 2023 | 39.41 Mn |
| Sep 30, 2023 | 42.10 Mn |
| Jun 30, 2023 | 23.46 Mn |
| Mar 31, 2023 | 33.48 Mn |
| Dec 31, 2022 | 36.72 Mn |
| Sep 30, 2022 | 39.31 Mn |
| Jun 30, 2022 | 26.16 Mn |
| Mar 31, 2022 | 35.98 Mn |
| Dec 31, 2021 | 58.12 Mn |
| Sep 30, 2021 | 21.33 Mn |